Related references
Note: Only part of the references are listed.JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles
Jaime A. Castro-Mondragon et al.
NUCLEIC ACIDS RESEARCH (2022)
Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation
Yuanyuan Yu et al.
NATURE COMMUNICATIONS (2022)
gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS
Mario S. Valdes-Tresanco et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2021)
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment A Phase 3 Randomized Clinical Trial
Thomas W. P. Friedl et al.
JAMA ONCOLOGY (2021)
Kinetic Analysis of a Protein-protein Complex to Determine its Dissociation Constant (KD) and the Effective Concentration (EC50) of an Interplaying Effector Molecule Using Bio-layer Interferometry
Tim Orthwein et al.
BIO-PROTOCOL (2021)
Romosozumab: A first-in-class scierostin inhibitor for osteoprosis
Caitlin Prather et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2020)
Bone metastases
Robert E. Coleman et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness
Eric Hesse et al.
JCI INSIGHT (2019)
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
Michael R. McClung et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Bone-Targeted Therapies in Cancer-Induced Bone Disease
Sofia Sousa et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Romosozumab for the treatment of osteoporosis
Leonardo Bandeira et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer
Menghai Zhu et al.
SCIENTIFIC REPORTS (2017)
Sclerostin Inhibition in the Management of Osteoporosis
Natasha M. Appelman-Dijkstra et al.
CALCIFIED TISSUE INTERNATIONAL (2016)
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge
Duncan E. Scott et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins
Dima Kozakov et al.
NATURE PROTOCOLS (2015)
Using tumour phylogenetics to identify the roots of metastasis in humans
Kamila Naxerova et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Michelle R. Arkin et al.
CHEMISTRY & BIOLOGY (2014)
IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples
Frency Varghese et al.
PLOS ONE (2014)
FIPSDock: A new molecular docking technique driven by fully informed swarm optimization algorithm
Yu Liu et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2013)
Osteoporosis and Cancer
Matthew T. Drake
CURRENT OSTEOPOROSIS REPORTS (2013)
FTSite: high accuracy detection of ligand binding sites on unbound protein structures
Chi-Ho Ngan et al.
BIOINFORMATICS (2012)
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Sachin Surade et al.
CHEMISTRY & BIOLOGY (2012)
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy
Evangelos Terpos et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Structural biology and drug discovery for protein-protein interactions
Harry Jubb et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Osteoporosis: now and the future
Tilman D. Rachner et al.
LANCET (2011)
Cancer to bone: a fatal attraction
Katherine N. Weilbaecher et al.
NATURE REVIEWS CANCER (2011)
Sclerostin: Current Knowledge and Future Perspectives
M. J. C. Moester et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
RL Bezooijen et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
A multigenic program mediating breast cancer metastasis to bone
YB Kang et al.
CANCER CELL (2003)
Bisphosphonates induce breast cancer cell death in vitro
O Fromigue et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Share Paper
